Common Equity: The sum of all common equity items.
Tourmaline Bio, Inc. (TRML) had Common Equity of $279.86M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-22.97M |
|
-- |
|
-- |
|
$26.23M |
|
$-26.23M |
|
$3.26M |
|
$-22.97M |
|
$-22.97M |
|
$-22.97M |
|
$-22.97M |
|
$-22.97M |
|
$-22.97M |
|
$-26.23M |
|
$-27.78M |
|
25.69M |
|
25.69M |
|
$-0.89 |
|
$-0.89 |
|
| Balance Sheet Financials | |
$258.14M |
|
$0.06M |
|
$29.35M |
|
$287.50M |
|
$7.62M |
|
-- |
|
$0.01M |
|
$7.63M |
|
|
Common Equity |
$279.86M |
$279.86M |
|
$279.86M |
|
25.68M |
|
| Cash Flow Statement Financials | |
$-21.68M |
|
$25.94M |
|
$0.56M |
|
$30.73M |
|
$35.56M |
|
$4.82M |
|
$2.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
33.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-21.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.21% |
|
-8.21% |
|
-7.99% |
|
-8.21% |
|
$10.90 |
|
$-0.84 |
|
$-0.84 |
|